Democrats call for end to generic drug settlements

Share this article:
Sen. Charles Schumer (D-NY) and Rep. Henry Waxman (D-CA) have called on organizations representing innovator and generic drug companies to take a stance against the increase in settlements in which branded companies pay generics firms to keep generic drugs off the market.
The two said such settlements allow brand-name companies to pay generic firms to delay entry of their drugs into the market, decreasing competition and resulting in a drastic increase in the price of prescription drugs.

Schumer and Waxman said the settlements arise in the context of patent infringement lawsuits filed against generic firms.

“In many cases,” they said, “patent settlement agreements can provide great benefit, not only for the parties involved, by allowing them to avoid protracted litigation, but also for consumers, by speeding the entry of generic drugs that might otherwise have been deferred by the litigation.”
But they pointed out that since the late 1990s, settlements have often included agreements by generics firms to stay off the market in exchange for payments from brand-name firms.

Share this article:
close

Next Article in News

Email Newsletters

More in News

BMS Q2 sales slip, Eliquis, Yervoy soar

BMS Q2 sales slip, Eliquis, Yervoy soar

The company attributed part of the Eliquis boost to the BMS-Pfizer DTC and education efforts.

Gilead, Merck HCV marketing battle may be on horizon

Gilead, Merck HCV marketing battle may be on ...

Disclosed in its earnings report yesterday, Gilead may have a card up its sleeve to counter Merck's experimental hep. C combo regimen.

Sales of Biogen MS pill pick up overseas

Sales of Biogen MS pill pick up overseas

Biogen Idec is seeing strong sales for blockbuster MS drug Tecfidera, especially overseas where it's beginning to catch fire this summer.